ICH E8 General Considerations for Clinical Trials
E555142
ICH E8 General Considerations for Clinical Trials is an international guideline that outlines fundamental principles and quality considerations for the design, conduct, and evaluation of clinical studies across all phases of drug development.
All labels observed (1)
| Label | Occurrences |
|---|---|
| ICH E8 General Considerations for Clinical Trials canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T5932238 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: ICH E8 General Considerations for Clinical Trials Context triple: [ICH, notableGuideline, ICH E8 General Considerations for Clinical Trials]
-
A.
ICH E6 Good Clinical Practice
ICH E6 Good Clinical Practice is an international ethical and scientific quality standard that governs the design, conduct, recording, and reporting of clinical trials involving human subjects.
-
B.
Pharmacovigilance Risk Assessment Committee within the European Medicines Agency
The Pharmacovigilance Risk Assessment Committee within the European Medicines Agency is an expert body responsible for evaluating and monitoring the safety of medicines across the European Union and providing recommendations on managing and communicating medicine-related risks.
-
C.
ICH E2A Clinical Safety Data Management
ICH E2A Clinical Safety Data Management is an international guideline that standardizes the collection, reporting, and evaluation of clinical safety data in drug development to support consistent pharmacovigilance and regulatory decision-making.
-
D.
ICH Q8 Pharmaceutical Development
ICH Q8 Pharmaceutical Development is an international guideline that outlines a systematic, science- and risk-based approach to pharmaceutical product and process development, forming a core part of the ICH quality framework.
-
E.
Conditional Marketing Authorization by European Medicines Agency
Conditional Marketing Authorization by the European Medicines Agency is a fast-track regulatory pathway that allows earlier approval of medicines, such as COVID-19 vaccines, based on less comprehensive data than normally required, provided that the benefits outweigh the risks and additional data will be supplied post-approval.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: ICH E8 General Considerations for Clinical Trials Target entity description: ICH E8 General Considerations for Clinical Trials is an international guideline that outlines fundamental principles and quality considerations for the design, conduct, and evaluation of clinical studies across all phases of drug development.
-
A.
ICH E6 Good Clinical Practice
ICH E6 Good Clinical Practice is an international ethical and scientific quality standard that governs the design, conduct, recording, and reporting of clinical trials involving human subjects.
-
B.
Pharmacovigilance Risk Assessment Committee within the European Medicines Agency
The Pharmacovigilance Risk Assessment Committee within the European Medicines Agency is an expert body responsible for evaluating and monitoring the safety of medicines across the European Union and providing recommendations on managing and communicating medicine-related risks.
-
C.
ICH E2A Clinical Safety Data Management
ICH E2A Clinical Safety Data Management is an international guideline that standardizes the collection, reporting, and evaluation of clinical safety data in drug development to support consistent pharmacovigilance and regulatory decision-making.
-
D.
ICH Q8 Pharmaceutical Development
ICH Q8 Pharmaceutical Development is an international guideline that outlines a systematic, science- and risk-based approach to pharmaceutical product and process development, forming a core part of the ICH quality framework.
-
E.
Conditional Marketing Authorization by European Medicines Agency
Conditional Marketing Authorization by the European Medicines Agency is a fast-track regulatory pathway that allows earlier approval of medicines, such as COVID-19 vaccines, based on less comprehensive data than normally required, provided that the benefits outweigh the risks and additional data will be supplied post-approval.
- F. None of above. chosen
Statements (48)
| Predicate | Object |
|---|---|
| instanceOf |
ICH guideline
ⓘ
clinical trial guideline ⓘ regulatory guidance document ⓘ |
| abbreviation | ICH E8 NERFINISHED ⓘ |
| addresses |
ethical conduct of clinical trials
ⓘ
protection of trial subjects ⓘ quality by design in clinical development ⓘ reliability of clinical trial data ⓘ risk-based approach to clinical trial quality ⓘ scientific validity of clinical trials ⓘ |
| aimsTo |
facilitate global drug registration
ⓘ
harmonise clinical trial requirements internationally ⓘ improve quality of clinical development programs ⓘ |
| appliesTo |
all phases of clinical drug development
ⓘ
confirmatory clinical trials ⓘ exploratory clinical trials ⓘ post-approval clinical studies ⓘ |
| covers |
blinding and randomisation
ⓘ
choice of endpoints ⓘ control groups and comparators ⓘ data handling and record keeping ⓘ monitoring and quality assurance ⓘ multinational clinical trials ⓘ selection of trial population ⓘ special populations in clinical trials ⓘ |
| emphasizes |
critical-to-quality factors in clinical trials
ⓘ
patient safety and rights ⓘ proportionate trial oversight ⓘ prospective planning of trial quality ⓘ |
| focusesOn |
general principles for clinical trials
ⓘ
quality considerations in clinical studies ⓘ |
| hasFullTitle | ICH Harmonised Guideline E8: General Considerations for Clinical Trials NERFINISHED ⓘ |
| intendedFor |
clinical investigators
ⓘ
ethics committees ⓘ pharmaceutical sponsors ⓘ regulatory authorities ⓘ |
| issuedBy | International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use NERFINISHED ⓘ |
| language | English ⓘ |
| providesGuidanceOn |
analysis of clinical trial data
ⓘ
conduct of clinical trials ⓘ design of clinical trials ⓘ documentation of clinical trials ⓘ interpretation of clinical trial results ⓘ |
| relatedTo |
ICH E6 Guideline for Good Clinical Practice
NERFINISHED
ⓘ
ICH E9 Statistical Principles for Clinical Trials NERFINISHED ⓘ |
| scope | human clinical trials of medicinal products ⓘ |
| usedIn |
design of clinical trial protocols
ⓘ
regulatory review of clinical development programs ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: ICH E8 General Considerations for Clinical Trials Description of subject: ICH E8 General Considerations for Clinical Trials is an international guideline that outlines fundamental principles and quality considerations for the design, conduct, and evaluation of clinical studies across all phases of drug development.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.